Home Contact Sitemap login Checkout

BioAlberta
  • Home
  • About
    • About
    • The BioAlberta Team
    • From The President
    • What We Do
    • Board of Directors
    • Committees
    • Industry Partners
    • Hall Of Fame
  • Talent Hub
    • Talent Hub
    • Alberta Petri Dish
    • WIL
    • Boosting Biotech
  • Industry Facts
    • Industry Facts
    • Medical Technology & Devices
    • Health Biotechnology & Pharmaceuticals
    • Agricultural Biotechnology
    • Industrial Biotechnology
    • Functional Foods & Natural Health Products
    • Environmental Biotechnology
    • Industry Terms
  • Events
    • Events
    • Alberta at Bio International 2022
    • Annual Events & Activities
    • Archived Events
      • Archived Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
      • 2017 Events
      • 2016 Events
      • 2015 Events
      • 2014 Events
  • News
    • News
    • Archived News
      • Archived News
      • 2020 News
      • 2019 News
      • 2018 News
      • 2017 news
      • 2016 News
      • 2015 News
      • 2014 News
  • Member Area
    • Member Area
    • Member Marketplace
    • Join Now
    • Member Benefits
      • Member Benefits
      • How To Access Member Benefits
    • Current Members and Life Sciences Industry
    • Current Members by Category
    • Profiled Company
      • Profiled Company
      • Previously Profiled Companies
  • Resources
    • Resources
    • Other Resources
  • Contact
Print This Page

Entos Pharmaceuticals CEO John Lewis Featured in Edmonton Journal

John Lewis, CEO of BioAlberta member Entos Pharmaceuticals, and a lead research scientist at the Alberta Prostate Cancer Initiative, was featured in the Edmonton Journal discussing the potential of ultrasound as a prostate cancer biopsy tool.

 

Invasive biopsies that are currently required for diagnosis and treatment of prostate cancer could one day be replaced with relatively painless ultrasounds, say researchers at the University of Alberta.  Prostate cancer patients are expected to undergo frequent biopsies to help their doctors understand the progression and nature of the disease.

 

“A biopsy involves 14 needles through a walnut-size gland, the prostate. As you might imagine, it’s a very uncomfortable and invasive procedure,” said John Lewis, associate professor of oncology at the U of A and a cancer biologist involved in a new study.

 

Lewis and his team hope to replace these biopsies with a combination of ultrasound and nanotechnology. The procedure will use high-intensity focused ultrasound and nanoparticles that increase the detection of cancer biomarkers in the blood.

 

Read Sharon Nadeem's article here.

Contact Us
Suite 202
10055 - 106 Street NW
Edmonton, Alberta T5J 2Y2
Canada
Ph:  780.425.3804
Fx:  780.409.9263
admin@BioAlberta.com
Quick Links
Home
About
Industry Facts
News
Events
Member Area
Publications
Contact
Return Policy
Privacy
Terms of Use
Connect
BioAlberta: Twitter linkBioAlberta: linkedin linkBioAlberta: YouTube linkBioAlberta: facebook link